Anteris Technologies Global Corp. Common Stock(AVR)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$5.42
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for AVR

11/13/2026: AVR (1-star) is currently NOT-A-BUY. Pass it for now.

Anteris Technologies Global Corp. is a clinical-stage medical device company focused on developing advanced structural heart solutions, led by its flagship DurAVR Transcatheter Heart Valve. The company's primary strength lies in its innovative biomimetic design and proprietary ADAPT tissue technology, which aim to deliver superior hemodynamic performance and durability. Its core investment narrative centers on the potential clinical validation and commercialization of its valve system within a multi-billion-dollar aortic stenosis market. However, the company faces substantial execution risks, high cash burn, regulatory hurdles, and intense competition from entrenched medical device giants. Anteris suits growth-oriented investors with a high risk tolerance who are willing to monitor clinical trial readouts, regulatory milestones, and liquidity management closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitAnteris offers high-growth exposure to novel structural heart medical technologies backed by expanding clinical trials.
Momentum investorStrong fit while signal remains positiveThe stock experiences notable price swings tied to clinical data readouts and regulatory announcements.
Value investorWeak fitThe company currently operates at a net loss with minimal commercial revenues and high development cash burns.
Dividend investorWeak fitAnteris pays no dividends, focusing entirely on reinvesting capital into research and clinical expansion.
Low-risk investorWeak fitClinical-stage regulatory and funding dependencies introduce substantial volatility and binary risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighStock valuations fluctuate sharply in response to clinical trial milestones, regulatory updates, and market sentiment.
Valuation riskMedium / highPricing is heavily forward-looking, depending on future commercial success rather than current earnings.
Competition risk (incumbent medtech dominance)HighThe company competes against massive, well-resourced medical device conglomerates with entrenched hospital contracts.
Business qualityMediumWhile technology potential is high, the commercial-stage operational infrastructure is still maturing.
Dividend incomeLow / noneNo dividend distributions are paid to shareholders.
Execution riskHighSuccess relies heavily on flawless clinical trial execution, regulatory approvals, and eventual market adoption.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 528.41M USD
Price to earnings Ratio -
1Y Target Price 13.75
Price to earnings Ratio -
1Y Target Price 13.75
Volume (30-day avg) 1.6M shares
Beta 0.73
52 Weeks Range 3.30 - 11.05
Updated Date 11/15/2026
52 Weeks Range 3.30 - 11.05
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.6

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -40.74%
Avg. Invested days 16
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
AVR receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
AVR has moderate overall fundamentals (3 stars), with weak financial health, soft growth momentum, and strong ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-23.4%), weak cash generation (FCF margin -4169.2%), negative revenue growth (-29.2%).

Financial Health Rating

★★★★★
AVR's financial health is weak, with the relatively strongest area being soft cash strength, including free-cash-flow generation (-4169.2% of revenue). Operating efficiency is weak (1 stars), which helps explain the 1-star overall score.

Growth Momentum Score

★★★★★
AVR's growth profile is soft, with the least-weak measure being earnings growth at -23.4% FY2025 versus FY2024. By comparison, while revenue growth (-29.2%, negative) and free-cash-flow growth (-25.6%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 72.3% and approximately 70.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 16.86% supports management-shareholder alignment.

Top 5 Institutional Investors

L1 Capital Pty Ltd 7.99%
FMR Inc 7.04%
Nantahala Capital Management, LLC 6.94%
BlackRock Inc 5.92%
Sio Capital Management, LLC 5.69%

Unit Economics (Per $1K Revenue)

★★★★★
AVR generates approximately $-166 of gross profit, $-49,082 of operating income, and $-41,692 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
AVR has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Medical Device Commercialization & Clinical Humanitarian AccessEarly-stage commercial and investigational sales of structural heart valve systems across limited international regions.The company is primarily pre-revenue on a scale basis, with future financial returns resting entirely on clinical adoption and regulatory approvals.
Geography (United States & International)Operations spanning the United States, Germany, Australia, Switzerland, and Sweden.Revenue generation and clinical trial footprint are concentrated primarily in the US and Western Europe.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 312.23M
Price to Sales(TTM) 226.59
Enterprise Value 312.23M
Price to Sales(TTM) 226.59
Enterprise Value to Revenue 133.89
Enterprise Value to EBITDA -
Shares Outstanding 97.49M
Shares Floating 68.73M
Shares Outstanding 97.49M
Shares Floating 68.73M
Percent Insiders 16.86
Percent Institutions 72.31

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.